Scalper1 News
Specialty drugmaker Mallinckrodt beat analysts’ expectations handily in its fiscal Q4 report, but it didn’t provide hoped-for guidance in the wake of an FDA decision that hits one of its best-selling drugs. Mallinckrodt (MNK) stock was down 4% in early trading on the stock market today, near 85, and is now down more than 10% since touching an all-time high of 95.74 on Nov. 5. For its fiscal fourth quarter, which ended Sept. 26, Mallinckrodt made Scalper1 News
Scalper1 News